Allergy Therapeutics PLC Appointment of Nominated Adviser and Sole Broker
July 22 2024 - 2:00AM
RNS Regulatory News
RNS Number : 1708X
Allergy Therapeutics PLC
22 July 2024
![Porto](https://dw6uz0omxro53.cloudfront.net/3115250/92aeb5d8-ad7d-47af-8002-b0ad30468d1a.png)
Allergy Therapeutics
plc
("Allergy
Therapeutics" or the "Company" or the "Group")
Appointment of Nominated
Adviser and Corporate Broker
22 July 2024: Allergy
Therapeutics (AIM: AGY), the fully integrated commercial
biotechnology company specialising in allergy vaccines, is pleased
to announce the appointment of Cavendish Capital Markets Limited as
Nominated Adviser and Corporate Broker with immediate
effect.
- ENDS
-
For
further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
Geoff Nash /Giles Balleny/Seamus
Fricker / Rory Sale
Nigel Birks/Tamar Cranford Smith -
Sales
+44 (0)20 7220 0500
ICR
Consilium
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
About Allergy Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that
have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
includes vaccines for grass, tree, house dust mite and peanut. For
more information, please see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPGPUPWMUPCGQB
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Sep 2023 to Sep 2024